Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691652 · ClinicalTrials.gov registry record · Phase 1
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00691652 is a Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT00691652, a Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving clofarabine together with rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when given together with rituximab and to see how well they work in treating patients with relapsed B-cell non-Hodgkin lymphoma.
Interventions
- GENETIC gene expression analysis
- GENETIC microarray analysis
- BIOLOGICAL rituximab
- DRUG clofarabine
- GENETIC DNA methylation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691652
The ClinicalTrials.gov registry entry for NCT00691652 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00691652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00691652 about?
NCT00691652 is a clinical study titled "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma". RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer ...
What is the current status of trial NCT00691652?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00691652?
The interventions under investigation include: gene expression analysis (GENETIC), microarray analysis (GENETIC), rituximab (BIOLOGICAL), clofarabine (DRUG), DNA methylation analysis (GENETIC).
Who is sponsoring clinical trial NCT00691652?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.